- Home
- IBOC vs LGND Comparison
IBOC vs LGND Comparison
Compare IBOC & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- LGND
- Stock Information
- Founded
- IBOC 1966
- LGND 1987
- Country
- IBOC United States
- LGND United States
- Employees
- IBOC N/A
- LGND 68
- Industry
- IBOC Major Banks
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- IBOC Finance
- LGND Health Care
- Exchange
- IBOC Nasdaq
- LGND Nasdaq
- Market Cap
- IBOC 3.8B
- LGND 3.2B
- IPO Year
- IBOC N/A
- LGND 1992
- Fundamental
- Price
- IBOC $71.58
- LGND $166.75
- Analyst Decision
- IBOC
- LGND Strong Buy
- Analyst Count
- IBOC 0
- LGND 8
- Target Price
- IBOC N/A
- LGND $144.71
- AVG Volume (30 Days)
- IBOC 205.9K
- LGND 139.7K
- Earning Date
- IBOC 08-07-2025
- LGND 08-05-2025
- Dividend Yield
- IBOC 1.96%
- LGND N/A
- EPS Growth
- IBOC 1.85
- LGND N/A
- EPS
- IBOC 6.61
- LGND N/A
- Revenue
- IBOC $808,643,000.00
- LGND $181,488,000.00
- Revenue This Year
- IBOC N/A
- LGND $18.41
- Revenue Next Year
- IBOC N/A
- LGND $18.87
- P/E Ratio
- IBOC $10.96
- LGND N/A
- Revenue Growth
- IBOC 1.28
- LGND 53.40
- 52 Week Low
- IBOC $54.11
- LGND $81.74
- 52 Week High
- IBOC $76.91
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- IBOC 56.18
- LGND 75.21
- Support Level
- IBOC $70.35
- LGND $158.40
- Resistance Level
- IBOC $73.47
- LGND $161.89
- Average True Range (ATR)
- IBOC 1.38
- LGND 3.32
- MACD
- IBOC 0.05
- LGND 0.09
- Stochastic Oscillator
- IBOC 65.40
- LGND 86.29
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.